A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect

MLA

Lu Feng, et al. “A Novel Therapeutic Vaccine Composed of a Rearranged Human Papillomavirus Type 16 E6/E7 Fusion Protein and Fms-like Tyrosine Kinase-3 Ligand Induces CD8+ T Cell Responses and Antitumor Effect.” Vaccine, vol. 35, Nov. 2017, pp. 6459–67. EBSCOhost, https://doi.org/10.1016/j.vaccine.2017.09.003.

APA

Lu Feng, Chen Si, Li Jianqiang, Ge Jun, Yueqing Gu, Pu Xiuying, Chen Xiaoxiao, Sun Jiaojiao, Ren Sulin, & Zhao Zhiqiang. (2017). A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect. Vaccine, 35, 6459–6467. https://doi.org/10.1016/j.vaccine.2017.09.003

Chicago

Lu Feng, Chen Si, Li Jianqiang, Ge Jun, Yueqing Gu, Pu Xiuying, Chen Xiaoxiao, Sun Jiaojiao, Ren Sulin, and Zhao Zhiqiang. 2017. “A Novel Therapeutic Vaccine Composed of a Rearranged Human Papillomavirus Type 16 E6/E7 Fusion Protein and Fms-like Tyrosine Kinase-3 Ligand Induces CD8+ T Cell Responses and Antitumor Effect.” Vaccine 35 (November): 6459–67. doi:10.1016/j.vaccine.2017.09.003.